secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bausch & Lomb Corp (BLCO)
CIK:        0001860742
Form:       8-K
Filed at:   2023-09-06T23:59:59+00:00
Accession:  0001193125-23-229767
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bausch + Lomb provides financials for Novartis XIIDRA acquisition; $1.75B upfront plus $750M milestones
--------------------------------------------------------------------------------

- Acquisition of XIIDRA (lifitegrast) and certain ophthalmology assets from Novartis for $1.75B upfront and up to $750M milestone payments.
- Closing expected at or around end of September 2023, subject to customary conditions.
- Acquired assets had net revenue of $487M in 2022 and $468M in 2021, with total comprehensive shortfall of $384M in 2022.
- Net assets acquired were $2.065B as of Dec 31, 2022, including $2.138B intangible asset.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860742/000119312523229767/0001193125-23-229767-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860742/000119312523229767/d548500d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-229767

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer